Moomoo AI 已提取核心信息
TransCode Therapeutics, Inc., a biopharmaceutical company, was the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC), dated December 31, 2023. The amendment was filed by Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang, the manager of Tang Capital Management. The filing indicates that these entities and individual collectively own 0 shares of TransCode Therapeutics' common stock and consequently represent 0.0% of the class. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is typically used by persons who have acquired beneficial ownership of more than 5% of a class of equity securities. The filing also includes a certification by Kevin Tang, stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The principal business office address for the reporting persons is listed as 4747 Executive Drive, Suite 210, San Diego, CA 92121.
TransCode Therapeutics, Inc., a biopharmaceutical company, was the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC), dated December 31, 2023. The amendment was filed by Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang, the manager of Tang Capital Management. The filing indicates that these entities and individual collectively own 0 shares of TransCode Therapeutics' common stock and consequently represent 0.0% of the class. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is typically used by persons who have acquired beneficial ownership of more than 5% of a class of equity securities. The filing also includes a certification by Kevin Tang, stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The principal business office address for the reporting persons is listed as 4747 Executive Drive, Suite 210, San Diego, CA 92121.
生物制药公司TransCode Therapeutics, Inc. 是最近于2023年12月31日向美国证券交易委员会（SEC）提交的附表13G/A文件的主题。该修正案由唐资本合伙人有限责任公司、唐资本管理有限责任公司和唐资本管理公司经理唐凯文提交。文件显示，这些实体和个人共拥有TransCode Therapeutics普通股的0股，因此占该类别的0.0％。该申请是根据1934年《证券交易法》第13d-1（c）条提交的，该法通常由获得某类股票证券5％以上的受益所有权的人使用。该文件还包括唐凯文的证明，表明收购这些股票不是为了改变或影响发行人的控制权，也不是与任何具有此类目的或效果的交易有关。申报人的主要办公地址列为行政大道4747号，210套房，加利福尼亚州圣地亚哥92121。
生物制药公司TransCode Therapeutics, Inc. 是最近于2023年12月31日向美国证券交易委员会（SEC）提交的附表13G/A文件的主题。该修正案由唐资本合伙人有限责任公司、唐资本管理有限责任公司和唐资本管理公司经理唐凯文提交。文件显示，这些实体和个人共拥有TransCode Therapeutics普通股的0股，因此占该类别的0.0％。该申请是根据1934年《证券交易法》第13d-1（c）条提交的，该法通常由获得某类股票证券5％以上的受益所有权的人使用。该文件还包括唐凯文的证明，表明收购这些股票不是为了改变或影响发行人的控制权，也不是与任何具有此类目的或效果的交易有关。申报人的主要办公地址列为行政大道4747号，210套房，加利福尼亚州圣地亚哥92121。
有用
没用
